Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1684-1692

  Endimiani, Andrea ^a,b,c   Blackford, Martha ^d   Dasenbrook, Elliot C ^a,e   Reed, Michael D ^d   Bajaksouszian, Saralee ^a   Hujer, Andrea M ^a,b   Rudin, Susan D ^a,b   Hujer, Kristine M ^a,b   Perreten, Vincent ^c   Rice, Louis B ^b   Jacobs, Michael R ^a   Konstan, Michael W ^e   Bonomo, Robert A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d AKRON CHILDREN'S HOSPITAL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; PEPTIDYLTRANSFERASE; RIBOSOME RNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; CYSTIC FIBROSIS; ESCHERICHIA COLI; FEMALE; GEL ELECTROPHORESIS; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; UNITED STATES;

ACETAMIDES; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; MALE; OXAZOLIDINONES; POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 79953217058     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01308-10     Document Type: Article

References (47)

1. Abunasser, J., and M. L. Metersky. 2009. A comparison of linezolid with glycopeptides in severe MRSA pneumonia. Expert Rev. Anti Infect. Ther. 7:951-955.
2. Besier, S., A. Ludwig, J. Zander, V. Brade, and T. A. Wichelhaus. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52:1570-1572.
3. Boak, L. M., J. Li, C. R. Rayner, and R. L. Nation. 2007. Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob. Agents Chemother. 51:1287-1292.
4. Bosso, J. A., P. A. Flume, and S. L. Gray. 2004. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:281-284.
5. Carias, L. L., S. D. Rudin, C. J. Donskey, and L. B. Rice. 1998. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycinresistant Enterococcus faecium isolate. J. Bacteriol. 180:4426-4434.
6. Chambers, H. F., and F. R. Deleo. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641.
7. CLSI. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. CLSI, Wayne, PA.
8. Cystic Fibrosis Foundation. 2009. Patient registry 2008. Annual report. Cystic Fibrosis Foundation, Bethesda, MD.
9. Dasenbrook, E. C., et al. 2010. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303:2386-2392.
10. Dasenbrook, E. C., W. Checkley, C. A. Merlo, N. Lechtzin, and M. Boyle. 2009. MRSA is associated with increased mortality: a 10-year cohort study of the National Patient Registry. Pediatr. Pulmonol. S32:310-311.
11. Dasenbrook, E. C., C. A. Merlo, M. Diener-West, N. Lechtzin, and M. P. Boyle. 2008. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:814-821.
12. Enright, M. C., N. P. Day, C. E. Davies, S. J. Peacock, and B. G. Spratt. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.
13. European Committee on Antimicrobial Susceptibility Testing. 2010. MIC distributions. http://www.eucast.org/. Accessed 8 March 2010.
14. Ferrin, M., J. B. Zuckerman, A. Meagher, and E. A. Blumberg. 2002. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33:221-223.
15. Gales, A. C., et al. 2006. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27:300-302.
16. Gilbert, D. N., R. C. Moellering, G. M. Eliopoulos, H. F. Chambers, and S. M. S. 2009. The Sanford guide to antimicrobial therapy, 39th ed. Antimicrobial Therapy, Inc., Sperryville, VA.
17. Hall, T. A., et al. 2009. Rapid molecular genotyping and clonal complex assignment of Staphylococcus aureus isolates by PCR coupled to electrospray ionization-mass spectrometry. J. Clin. Microbiol. 47:1733-1741.
18. Harmsen, D., et al. 2003. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J. Clin. Microbiol. 41:5442-5448.
19. Hill, R. L., et al. 2010. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J. Antimicrob. Chemother. 65:442-445.
20. Jones, R. N., J. E. Ross, M. Castanheira, and R. E. Mendes. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62:416-426.
21. Kehrenberg, C., and S. Schwarz. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163.
22. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
23. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
24. Meka, V. G., et al. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
25. Mendes, R. E., et al. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
26. Moellering, R. C. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138:135-142.
27. Molina, A., et al. 2008. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J. Antimicrob. Chemother. 62:961-967.
28. Morales, G., et al. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50:821-825.
29. O'Hara, F. P., et al. 2008. A geographic variant of the Staphylococcus aureus Panton-Valentine leukocidin toxin and the origin of community-associated methicillin-resistant S. aureus USA300. J. Infect. Dis. 197:187-194.
30. Peeters, M. J., and J. C. Sarria. 2005. Clinical characteristics of linezolidresistant Staphylococcus aureus infections. Am. J. Med. Sci. 330:102-104.
31. Pillai, S. K., et al. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
32. Ratnaraja, N. V., and P. M. Hawkey. 2008. Current challenges in treating MRSA: what are the options? Expert Rev. Anti Infect. Ther. 6:601-618.
33. Razvi, S., et al. 2009. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 136:1554-1560.
34. Rey, E., J. M. Treluyer, and G. Pons. 1998. Drug disposition in cystic fibrosis. Clin. Pharmacokinet. 35:313-329.
35. Sader, H. S., and R. N. Jones. 2009. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn. Microbiol. Infect. Dis. 65:158-162.
36. Sanchez Garcia, M., et al. 2010. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303:2260-2264.
37. Santos, R. P., et al. 2009. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr. Pulmonol. 44:148-154.
38. Saralaya, D., et al. 2004. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 53:325-328.
39. Serisier, D. J., G. Jones, and M. Carroll. 2004. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J. Cyst Fibros. 3:61. (Pubitemid 38397026)
40. Shopsin, B., et al. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J. Clin. Microbiol. 37:3556-3563.
41. Tacconelli, E., and G. De Angelis. 2009. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr. Opin. Pulm. Med. 15:218-222.
42. Tenover, F. C., et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
43. Toh, S. M., et al. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
44. Tsiodras, S., et al. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208. (Pubitemid 32718546)
45. Willems, R. J., et al. 2003. Mutations in the DNA mismatch repair proteins MutS and MutL of oxazolidinone-resistant or -susceptible Enterococcus faecium. Antimicrob. Agents Chemother. 47:3061-3066.
46. Wolk, D. M., et al. 2009. Pathogen profiling: rapid molecular characterization of Staphylococcus aureus by PCR/electrospray ionization-mass spectrometry and correlation with phenotype. J. Clin. Microbiol. 47:3129-3137.
47. Yoshida, K., et al. 2009. Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J. Infect. Chemother. 15:417-419.